Merck & Co., Inc. Debt Instrument, Fair Value Disclosure
Merck & Co., Inc. (MRK) had Debt Instrument, Fair Value Disclosure of $49.90 billion as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2026-08-07
- 2026-06-30: Debt Instrument, Fair Value Disclosure $49.90B.
- 2026-03-31: Debt Instrument, Fair Value Disclosure $44.70B.
- 2025-12-31: Debt Instrument, Fair Value Disclosure $45.60B.
- 2025-09-30: Debt Instrument, Fair Value Disclosure $37.70B.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $49.90B 10-Q · filed 2026-08-07 |
| 2026-03-31 | $44.70B 10-Q · filed 2026-05-04 |
| 2025-12-31 | $45.60B 10-Q · filed 2026-08-07 |
| 2025-09-30 | $37.70B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $31.30B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $30.60B 10-Q · filed 2025-05-02 |
| 2024-12-31 | $32.60B 10-K · filed 2026-02-24 |
| 2024-09-30 | $35.20B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $33.50B 10-Q · filed 2024-08-05 |
| 2024-03-31 | $30.40B 10-Q · filed 2024-05-03 |
| 2023-12-31 | $32.00B 10-K · filed 2025-02-25 |
| 2023-09-30 | $29.50B 10-Q · filed 2023-11-03 |
| 2023-06-30 | $34.00B 10-Q · filed 2023-08-07 |
| 2023-03-31 | $28.20B 10-Q · filed 2023-05-05 |
| 2022-12-31 | $26.70B 10-K · filed 2024-02-26 |
| 2022-09-30 | $25.90B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $29.00B 10-Q · filed 2022-08-05 |
| 2022-03-31 | $31.70B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $35.70B 10-K · filed 2023-02-24 |
| 2021-09-30 | $29.10B 10-Q · filed 2021-11-05 |
| 2021-06-30 | $29.50B 10-Q · filed 2021-08-09 |
| 2021-03-31 | $33.50B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $36.00B 10-K · filed 2022-02-25 |
| 2020-09-30 | $32.60B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $34.50B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $30.60B 10-Q · filed 2020-05-06 |
| 2019-12-31 | $28.80B 10-K · filed 2021-02-25 |
| 2019-09-30 | $28.70B 10-Q · filed 2019-11-05 |
| 2019-06-30 | $28.60B 10-Q · filed 2019-08-06 |
| 2019-03-31 | $27.10B 10-Q · filed 2019-05-08 |
| 2018-12-31 | $25.60B 10-K · filed 2020-02-26 |
| 2018-09-30 | $24.00B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $23.90B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $24.30B 10-Q · filed 2018-05-08 |
| 2017-12-31 | $25.60B 10-K · filed 2019-02-27 |
| 2017-09-30 | $28.30B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $26.00B 10-Q · filed 2017-08-08 |
| 2017-03-31 | $29.30B 10-Q · filed 2017-05-09 |
| 2016-12-31 | $25.70B 10-K · filed 2018-02-27 |
| 2016-09-30 | $27.00B 10-Q · filed 2016-11-07 |
| 2016-06-30 | $26.20B 10-Q · filed 2016-08-08 |
| 2016-03-31 | $27.20B 10-Q · filed 2016-05-09 |
| 2015-12-31 | $27.00B 10-K · filed 2017-02-28 |
| 2015-09-30 | $27.20B 10-Q · filed 2015-11-05 |
| 2015-06-30 | $26.90B 10-Q · filed 2015-08-06 |
| 2015-03-31 | $31.60B 10-Q · filed 2015-05-07 |
| 2014-12-31 | $22.50B 10-K · filed 2016-02-26 |
| 2014-09-30 | $29.00B 10-Q · filed 2014-11-10 |
| 2014-06-30 | $24.20B 10-Q · filed 2014-08-07 |
| 2014-03-31 | $28.90B 10-Q · filed 2014-05-08 |
| 2013-12-31 | $25.50B 10-K · filed 2015-02-27 |
| 2013-09-30 | $27.30B 10-Q · filed 2013-11-07 |
| 2013-06-30 | $29.00B 10-Q · filed 2013-08-07 |
| 2013-03-31 | $22.80B 10-Q · filed 2013-05-09 |
| 2012-12-31 | $22.80B 10-K · filed 2014-02-27 |
| 2012-09-30 | $22.10B 10-Q · filed 2012-11-09 |
| 2012-06-30 | $21.20B 10-Q · filed 2012-08-07 |
| 2012-03-31 | $20.00B 10-Q · filed 2012-05-08 |
| 2011-12-31 | $19.50B 10-K · filed 2013-02-28 |
| 2011-09-30 | $19.70B 10-Q · filed 2011-11-08 |
| 2011-06-30 | $18.80B 10-Q · filed 2011-08-08 |
| 2011-03-31 | $18.30B 10-Q · filed 2011-05-09 |
| 2010-12-31 | $18.70B 10-K · filed 2012-02-28 |
| 2010-09-30 | $19.50B 10-Q · filed 2010-11-08 |
| 2010-06-30 | $19.00B 10-Q · filed 2010-08-06 |
| 2009-12-31 | $17.70B 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |